ZyVersa Therapeutics, Inc. (ZVSA) Stock Analysis & Investment Frameworks
ZyVersa Therapeutics, Inc. (ZVSA) stock analysis on Invetso. Review ZyVersa Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
ZyVersa Therapeutics, Inc. Company Overview
- Exchange: Other OTC
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
ZyVersa Therapeutics, Inc. Key Financial Metrics
- Market Cap: $801496.00
- Revenue: $N/A
- ROE: 0.79%
- ROIC: -16.53%
- Dividend Yield: N/A
About ZyVersa Therapeutics, Inc.
ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. Furthermore, ZyVersa is advancing IC 100, a pioneering inflammasome ASC inhibitor positioned to tackle a wide array of inflammatory conditions. The company maintains its corporate headquarters in Weston, Florida.
ZyVersa Therapeutics, Inc. Investment Frameworks
Invetso analyzes ZyVersa Therapeutics, Inc. (ZVSA) across the following frameworks:
- ZyVersa Therapeutics, Inc. 10Y Growth Potential
- ZyVersa Therapeutics, Inc. Scenario Analysis
- ZyVersa Therapeutics, Inc. Risks & Opportunities
- ZyVersa Therapeutics, Inc. Economic Moat
- ZyVersa Therapeutics, Inc. Business Model
- ZyVersa Therapeutics, Inc. Management
- ZyVersa Therapeutics, Inc. SWOT Analysis
- ZyVersa Therapeutics, Inc. Porter's 5 Forces
- ZyVersa Therapeutics, Inc. PESTLE Analysis
- ZyVersa Therapeutics, Inc. ESG Analysis
